Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kyphoplasty & vertebroplasty cases in Kentucky: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (184 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 1,066 | 37% |
| 2020 | 9 | 799 | 41% |
| 2021 | 11 | 770 | 47% |
| 2022 | 6 | 641 | 52% |
| 2023 | 5 | 569 | 55% |
| 2024 | 5 | 575 | 57% |
| 2025 from claims | – | 691 558–811 | 58% |
| 2026 forecast | – | 689 540–865 | 59% |
| 2027 forecast | – | 689 511–911 | 60% |
| 2028 forecast | – | 689 488–951 | 60% |
| 2029 forecast | – | 689 468–988 | 61% |
| 2030 forecast | – | 689 451–1,022 | 62% |
Vertebral compression fracture augmentation; IR, pain, spine surgeons. Professional codes (what the surgeon bills): CPT 22513, 22514, 22510, 22511.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Kentucky; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 27% inpatient hospital, 52% hospital outpatient, 21% office. The share outside the hospital has moved +7 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 71 | 5,916−5%/yr | −5%/yr | 2.6 | 52% | 6,240 in 2030+0.9%/yr |
| Texas | 43 | 3,866−5.3%/yr | −5.3%/yr | 1.8 | 26% | 3,550 in 2030−1.4%/yr |
| Virginia | 21 | 1,869−3.9%/yr | −3.9%/yr | 1.8 | 28% | 2,170 in 2030+2.6%/yr |
| North Carolina | 16 | 1,376−9.2%/yr | −9.2%/yr | 1.4 | 27% | 1,380 in 20300%/yr |
| Georgia | 9 | 1,369−5.8%/yr | −5.8%/yr | 1.6 | 22% | 1,270 in 2030−1.2%/yr |
| Oklahoma | 16 | 1,356−6.7%/yr | −6.7%/yr | 2.8 | 48% | 1,260 in 2030−1.2%/yr |
| Tennessee | 12 | 1,040−6.3%/yr | −6.3%/yr | 1.5 | 60% | 1,070 in 2030+0.5%/yr |
| Maryland | 8 | 809+0.7%/yr | +0.7%/yr | 0.9 | 57% | 730 in 2030−1.6%/yr |
| Alabama | 5 | 752−5.3%/yr | −5.3%/yr | 1.7 | 33% | 680 in 2030−1.7%/yr |
| South Carolina | 7 | 691−9%/yr | −9%/yr | 1.0 | 12% | 870 in 2030+3.9%/yr |
| Arkansas | 11 | 674−8.7%/yr | −8.7%/yr | 1.8 | 37% | 540 in 2030−3.7%/yr |
| Louisiana | 3 | 600−4.7%/yr | −4.7%/yr | 1.4 | 24% | 620 in 2030+0.4%/yr |
| Mississippi | 7 | 578−8.4%/yr | −8.4%/yr | 1.5 | 34% | 660 in 2030+2.3%/yr |
| Delaware | 2 | 124−1.1%/yr | −1.1%/yr | 0.7 | 32% | 260 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 33 | 1,469−9.4%/yr | −9.4%/yr | 3.10.9× | 1% | 1,500 in 2030+0.4%/yr |
| Lumbar fusion | 33 | 1,251−4%/yr | −4%/yr | 2.60.8× | 1% | 1,500 in 2030+3.1%/yr |
| Cervical fusion & disc arthroplasty | 10 | 605−9.7%/yr | −9.7%/yr | 1.30.7× | 2% | 730 in 2030+3.1%/yr |
| SI joint fusion | 2 | 100−6.4%/yr | −6.4%/yr | 0.20.6× | 0% | 170 in 2030+8.9%/yr |
Kyphoplasty & vertebroplasty in every state, and its device makers · Every procedure market in Kentucky · Every state · Compare with Florida
Medtronic leads with 74% of company spending on these surgeons in 2025, +18 pts on 2024.
In 2025, 4 companies reported engagement with Kentucky’s surgeons worth $13K in consulting, speaking, meals and travel tied to these products, about $2,521 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.